| Literature DB >> 29667777 |
Xiaoling Guo1, Yong Chen2, Tingting Hong1, Xianwu Chen1, Yue Duan1, Chao Li1, Renshan Ge1,2.
Abstract
Leydig cell transplantation is a better alternative in the treatment of androgen-deficient males. The main purpose of this study was to investigate the effects of induced pluripotent stem cell-derived conditioned medium (iPS-CM) on the anti-apoptosis, proliferation and function of immature Leydig cells (ILCs), and illuminate the underlying mechanisms. ILCs were exposed to 200 μmol/L hydrogen peroxide (H2 O2 ) for 24 hours with or without iPS-CM treatments. Cell apoptosis was detected by flow cytometric analysis. Cell proliferation was assessed using cell cycle assays and EdU staining. The steroidogenic enzyme expressions were quantified with Western blotting. The results showed that iPS-CM significantly reduced H2 O2 -induced ILC apoptosis through down-regulation of autophagic and apoptotic proteins LC3-I/II, Beclin-1, P62, P53 and BAX as well as up-regulation of BCL-2, which could be inhibited by LY294002 (25 μmol/L). iPS-CM could also promote ILC proliferation through up-regulation of β-catenin and its target proteins cyclin D1, c-Myc and survivin, but was inhibited by XAV939 (10 μmol/L). The level of bFGF in iPS-CM was higher than that of DMEM-LG. Exogenous bFGF (20 ng/mL) or Wnt signalling agonist lithium chloride (LiCl) (20 mmol/L) added into DMEM-LG could achieve the similar effects of iPS-CM. Meanwhile, iPS-CM could improve the medium testosterone levels and up-regulation of LHCGR, SCARB1, STAR, CYP11A1, HSD3B1, CYP17A1, HSD17B3 and SF-1 in H2 O2 -induced ILCs. In conclusion, iPS-CM could reduce H2 O2 -induced ILC apoptosis through the activation of autophagy, promote proliferation through up-regulation of Wnt/β-catenin pathway and enhance testosterone production through increasing steroidogenic enzyme expressions, which might be used in regenerative medicine for future.Entities:
Keywords: apoptosis; immature Leydig cells; induced pluripotent stem cell-derived conditional medium; pathway; proliferation
Mesh:
Substances:
Year: 2018 PMID: 29667777 PMCID: PMC6010900 DOI: 10.1111/jcmm.13641
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Antibodies
| Antibody | Species | Vendor (city, state, catalogue) | WB |
|---|---|---|---|
| β‐Actin | Rabbit | Cell Signaling Technology (Danvers, MA, 12620S) | 1:1000 |
| LHCGR | Goat | Santa Cruz (Santa Cruz, CA, sc‐26343) | 1:1000 |
| SCARB1 | Rabbit | Abcam (San Francisco, CA, ab217318) | 1:1000 |
| STAR | Rabbit | Abcam (San Francisco, CA, ab133657) | 1:1000 |
| CYP11A1 | Rabbit | Santa Cruz (Santa Cruz, CA, sc‐18043) | 1:1000 |
| HSD3B1 | Rabbit | Abcam (San Francisco, CA, ab65156) | 1:2000 |
| CYP17A1 | Rabbit | Santa Cruz (Santa Cruz, CA, sc‐66850) | 1:1000 |
| HSD17B3 | Rabbit | Abcam (San Francisco, CA, Ab70088) | 1:2000 |
| SF‐1 | Rabbit | Santa Cruz (Santa Cruz, CA, sc‐10976) | 1:1000 |
| BAX | Rabbit | Cell Signaling technology (Danvers, MA, 2774S) | 1:1000 |
| BCL2 | Rabbit | Cell Signaling technology (Danvers, MA, 4223S) | 1:1000 |
| β‐catenin | Rabbit | Cell Signaling technology (Danvers, MA, 8480) | 1:1000 |
| Cyclin D1 | Mouse | Santa Cruz (Santa Cruz, CA, sc‐8396) | 1:2000 |
| c‐Myc | Mouse | Santa Cruz (Santa Cruz, CA, sc‐40) | 1:2000 |
| Survivin | Mouse | Santa Cruz (Santa Cruz, CA, sc‐73082) | 1:2000 |
| LC3‐I/II | Rabbit | Cell Signaling technology (Danvers, MA, 12741S) | 1:1000 |
| Beclin‐1 | Rabbit | Cell Signaling technology (Danvers, MA, 3495S) | 1:1000 |
| P62 | Rabbit | Cell Signaling technology (Danvers, MA, 39749S) | 1:1000 |
| P53 | Mouse | Cell Signaling technology (Danvers, MA, 2524S) | 1:1000 |
Figure 1Exploration the optimal proportion of DMEM‐LG/iPS‐supernatant and apoptosis model of H2O2‐induced immature Leydig cells (ILCs). (A) The proliferation viability of ILCs in different proportion of DMEM‐LG/iPS‐supernatant was analysed by CCK‐8. (B) The bright field of ILCs exposed to various concentrations of H2O2 under an inverted microscope. (C) The viability effect of iPS‐CM on ILCs exposed to H2O2 at various doses by CCK‐8 assay. Mean ± SE, n = 5. *P < .05, **P < .01, ***P < .001 designate significant differences when compared to control (1:0 or 0 μmol/L)
Figure 2iPS‐CM inhibited the apoptosis of H2O2‐induced immature Leydig cells (ILCs). (A) Annexin V and propidium iodide (PI) assay was used to analyse the cell apoptosis in different groups. (B) Quantification of the Annexin V and PI assay. (C) Mitochondrial membrane potential (▵Ψm) assay was used to analyse the loss of ▵Ψm of ILCs in different groups. (D) Quantification of ▵Ψm. (E) Induced reactive oxygen species (ROS) assay was used to analyse the generation of ROS in different groups. (F) Quantification of intracellular ROS. Mean ± SE, n = 3. *P < .05 (iPS‐CM+H2O2 vs control), **P < .01 (iPS‐CM+H2O2 or control vs control+H2O2) designate significant differences
Figure 3iPS‐CM suppressed BAX up‐regulation and BCl‐2 down‐regulation of H2O2‐induced immature Leydig cells (ILCs). (A) The protein expression of BAX in different groups. (B) The protein expression of BCL‐2 in different groups. Mean ± SE, n = 3. *P < .05 designates significant differences
Figure 4iPS‐CM promoted the proliferation viability of H2O2‐induced immature Leydig cells (ILCs). (A) The cell cycle assay was conducted to analyse the proliferation viability in different groups. (B) Quantification of the cell cycle distribution. (C) EdU staining images at an inverted fluorescence microscope. (D) Fluorescent density of EdU‐positive cells was detected by flow cytometry assays. (E) Quantification of the EdU‐positive cells. Mean ± SE, n = 3. *P < .05, **P < .01 designate significant differences. Scale bars 100 μm
Figure 5Medium testosterone (T) and protein expression levels of H2O2‐induced immature Leydig cells (ILCs) with or without iPS‐CM treatments. (A) Medium testosterone (T) levels in different groups. Leydig cell proteins: (B) Western blotting band in different groups, (C) quantification of protein levels. Mean ± SE, n = 3. *P < .05, **P < .01, ***P < .01 designate significant differences
Figure 6The potential mechanisms underlying the promotion of immature Leydig cell (ILC) anti‐apoptosis and proliferation by iPS‐CM. (A) Quantification of the bFGF levels of medium in different groups using ELISA. (B) Assessment of protein expression levels of LC3 I/II, Beclin‐1, P62 and P53 in different groups using Western blotting assays. (C) Quantification of Western blotting assays. (D) Assessment of protein expression levels of β‐catenin, cyclin D1, c‐Myc and survivin in different groups using Western blotting assays. (E) Quantification of Western blotting assays. (F) Diagram of the potential mechanisms underlying the promotion of ILC anti‐apoptosis and proliferation by iPS‐CM. Mean ± SE, n = 3. *P < .05, **P < .01, ***P < .01 designate significant differences